
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT
- About
Lucid Diagnostics Inc (LUCD)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: LUCD (1-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $3.62
1 Year Target Price $3.62
4 | Strong Buy |
2 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -33.02% | Avg. Invested days 21 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 106.15M USD | Price to earnings Ratio - | 1Y Target Price 3.62 |
Price to earnings Ratio - | 1Y Target Price 3.62 | ||
Volume (30-day avg) 6 | Beta 1.21 | 52 Weeks Range 0.73 - 1.80 | Updated Date 08/15/2025 |
52 Weeks Range 0.73 - 1.80 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.95 |
Earnings Date
Report Date 2025-08-13 | When - | Estimate -0.11 | Actual -0.1 |
Profitability
Profit Margin - | Operating Margin (TTM) -978.85% |
Management Effectiveness
Return on Assets (TTM) -82.33% | Return on Equity (TTM) -463.56% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 156998728 | Price to Sales(TTM) 24.35 |
Enterprise Value 156998728 | Price to Sales(TTM) 24.35 | ||
Enterprise Value to Revenue 36.01 | Enterprise Value to EBITDA -0.67 | Shares Outstanding 108195000 | Shares Floating 66851146 |
Shares Outstanding 108195000 | Shares Floating 66851146 | ||
Percent Insiders 34.45 | Percent Institutions 18.62 |
Upturn AI SWOT
Lucid Diagnostics Inc
Company Overview
History and Background
Lucid Diagnostics Inc. was founded in 2018. It focuses on developing and commercializing tools for early detection of esophageal cancer, specifically in patients with Barrett's esophagus.
Core Business Areas
- EsoGuardu00ae Esophageal DNA Test: Non-endoscopic diagnostic test to detect esophageal precancer and cancer in patients with Barrett's esophagus.
- EsoChecku00ae Esophageal Cell Collection Device: Device used to collect esophageal cells for subsequent analysis by the EsoGuard test.
Leadership and Structure
The company is led by a management team focused on commercialization and clinical development, structured with a board of directors and executive leadership.
Top Products and Market Share
Key Offerings
- EsoGuardu00ae Esophageal DNA Test: A laboratory-developed test (LDT) used to detect biomarkers associated with Barrett's esophagus and esophageal adenocarcinoma. Market share data is difficult to determine due to the limited adoption and fragmented nature of the market for early cancer detection tools. The competitors are mainly endoscopic surveillance procedures, and novel technologies from companies like Medtronic. Revenue information is not easily available due to the company's developmental stage.
- EsoChecku00ae Esophageal Cell Collection Device: A swallowable device used to collect cells for EsoGuard. This is used in combination with EsoGuard, making it a companion product. Market share data for collection devices specifically is not publicly available. Competitors in this market are traditional endoscopic methods and other cell sampling techniques.
Market Dynamics
Industry Overview
The industry involves early cancer detection, with a focus on non-invasive diagnostic methods. The sector is characterized by increasing demand for less invasive and more cost-effective diagnostic tools.
Positioning
Lucid Diagnostics is positioned as an innovator in non-endoscopic esophageal cancer detection. Its competitive advantage lies in the ease of use and patient comfort associated with its EsoCheck/EsoGuard system.
Total Addressable Market (TAM)
The TAM for esophageal cancer detection is estimated to be in the billions of dollars, considering the high prevalence of Barrett's esophagus. Lucid is positioned to capture a portion of this TAM through its novel, non-invasive approach. A definitive number is difficult to assess due to changing market conditions and adoption rates.
Upturn SWOT Analysis
Strengths
- Non-invasive technology
- Ease of use for both patients and physicians
- Potential for early cancer detection
- Proprietary EsoGuard test
Weaknesses
- Limited clinical adoption
- Dependence on third-party payers for reimbursement
- High cost of goods sold
- Needs more robust clinical data.
Opportunities
- Expansion of EsoGuard testing into primary care settings
- Increasing awareness of Barrett's esophagus
- Development of new biomarkers for cancer detection
- Partnerships with gastroenterology practices and hospitals.
Threats
- Competition from established endoscopic procedures
- Regulatory hurdles for new diagnostic tests
- Lack of insurance coverage for EsoGuard testing
- Slower than expected adoption by physicians
Competitors and Market Share
Key Competitors
- MDGL
- BSX
- JNJ
Competitive Landscape
Lucid Diagnostics offers a unique non-invasive solution, but faces competition from established endoscopic methods and larger medical device companies like Medtronic. Lucidu2019s advantage is its patient friendly approach but suffers from limited clinical data and adoption.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been slow, with gradual increases in revenue as the company works to drive adoption of its EsoGuard test.
Future Projections: Future growth is dependent on successful commercialization, expansion of insurance coverage, and clinical validation. Analyst estimates are speculative and depend on the company's ability to execute its business plan.
Recent Initiatives: Recent initiatives include expansion of the sales force, partnerships with gastroenterology practices, and efforts to secure reimbursement from third-party payers.
Summary
Lucid Diagnostics is an early-stage company with a novel non-invasive cancer detection technology. It faces significant challenges in driving adoption, securing reimbursement, and competing with established medical procedures. The company needs to generate more revenue and further validate its technology with additional clinical data. Success depends on the execution of its commercialization strategy and overcoming regulatory and payer hurdles.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Investor Presentations
- Analyst Reports
- Industry News and Publications
Disclaimers:
This analysis is based on publicly available information and should not be construed as investment advice. Financial data is subject to change and may not be perfectly accurate. Market share data is based on estimates and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Lucid Diagnostics Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2021-10-14 | Chairman & CEO Dr. Lishan Aklog M.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 72 | Website https://www.luciddx.com |
Full time employees 72 | Website https://www.luciddx.com |
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.